leisure time -WSS

leisure time

author：hotspot 2025-09-14 08:29:45 - browse：7

Tortoise and hare — Medical devices have historically been seen as having faster paths to market than their pharmacological counterparts. The growing requirement for cost-effectiveness trials may be slowing them down. Jonathan Elderfield/AP

When a colleague and I started our medical device company in 2009, we were in our second year at Harvard Medical School. Some classmates joked that they would still be in residency by the time we had moved on to our next big idea. We knew better — we expected it to be a long haul. Eight years into our journey, thousands of individuals have used our product in countries where it has been approved. But we have yet to gain approval in the U.S. — a long and expensive process.

In 2016, the United States Food and Drug Administration approved 22 new drugs, down from 45 approvals in 2015. The decline in drug discovery has been attributed to a variety of factors that include ballooning research and development expenses (the cost to develop a new drug is now estimated to be more than $2.5 billion), high rates of failure (a whopping 90 percent of Phase 1 candidates never make it to launch), and the complexity of human biology, which can thwart even the most promising candidates.

Medical devices have historically been viewed as having faster and lower-cost paths to market than their pharmacological counterparts: the average cost to develop high-risk, novel medical devices is estimated to be $94 million. After all, device engineers can leverage lower-cost animal models further into development than their pharmaceutical colleagues, the human clinical trials necessary for FDA approval are often smaller in scale, and, in some cases, expenses can be defrayed by revenue generated outside the United States in markets with faster regulatory pathways.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Apple is now the first public company to be valued at $3 trillion
Next article： Mom launches Girl Scout troop for LGBTQ youth in Texas

hotspot

focus

WSS

Synthetic human embryos? Researchers say term is overblown

Illumina to lay off 10% of research and development team

Brazil's Jair Bolsonaro is barred from running for office until 2030

Lilly’s obesity pill cuts 15% of weight at highest dose in mid

Bispecific antibodies are next new thing in cancer immunotherapy

Altering the blood type of lungs raises potential for universal organs for transplants

hotspot

leisure time

entertainment

Moonlake's readout produced a cash windfall. Risks remain

How to fix the rural physician shortage in the U.S.

After affirmative action ruling, medical educators look to 'holistic review'

Biden slams SCOTUS affirmative action decision: 'Discrimination still exists in America'

ChatGPT in medicine: STAT answers readers' burning questions

Thousands protest in Iraq for a second day over burning of Quran in Sweden

Medical leaders decry Supreme Court decision on affirmative action

ADA: All diabetes patients should be screened for liver condition

Duchenne breakthrough therapy leaves behind pioneering families

New lesbian bars spark hope amid disappearing LGBTQ+ spaces

focus

Over 1,300 arrested in France in 4th night of protests over fatal police shooting of teen Nahel M.

How to fix the rural physician shortage in the U.S.

GOP inquiry over gain

Illumina to lay off 10% of research and development team

FDA approves first new drug developed for postpartum depression

We're not in Australia anymore: Kansas cops jump into action to save kangaroo

knowledge

hotspot

focus

knowledge